Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.
Journal
Current opinion in hematology
ISSN: 1531-7048
Titre abrégé: Curr Opin Hematol
Pays: United States
ID NLM: 9430802
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
28
10
2019
medline:
8
1
2021
entrez:
26
10
2019
Statut:
ppublish
Résumé
WHIM syndrome (warts, hypogammaglobulinemia, immunodeficiency, myelokathexis, or WHIMs) is a very rare autosomal dominant immunodeficiency disorder attributable to mutations in CXCR4. We reviewed clinical manifestations in 24 patients in 9 families to expand understanding of this syndrome. Warts, cellulitis and respiratory infections are common in patients with WHIMs. Less commonly these patients have congenital heart disease, human papilloma virus-associated malignancies (cervical and vulvular) and lymphomas. Hearing loss because of recurrent otitis media is another important complication. Treatment with granulocyte colony-stimulating factor is controversial; this review indicates that it is effective to prevent and treat infections based upon long-term observations of patients enrolled in the Severe Chronic Neutropenia International Registry. Understanding the natural history and diversity of this syndrome are important for ongoing clinical trials of novel agents to treat WHIMs. WHIM syndrome has diverse manifestations; some features occur consistently in almost all patients, for example, neutropenia, lymphocytopenia and mild hypogammaglobulinemia. However, the clinical consequences are quite variable across patient cohorts and within families. Each complication is important as a cause for morbidity and a source for patient and family concerns.
Identifiants
pubmed: 31652152
doi: 10.1097/MOH.0000000000000554
pmc: PMC7241424
mid: NIHMS1589212
pii: 00062752-202001000-00004
doi:
Substances chimiques
CXCR4 protein, human
0
Receptors, CXCR4
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-17Subventions
Organisme : NIAID NIH HHS
ID : R24 AI049393
Pays : United States
Références
Nat Genet. 2003 May;34(1):70-4
pubmed: 12692554
N Engl J Med. 1964 May 7;270:973-9
pubmed: 14122792
Int J Mol Sci. 2018 Dec 20;20(1):
pubmed: 30577453
N Engl J Med. 1964 Apr 2;270:699-704
pubmed: 14101065
Blood. 2011 Nov 3;118(18):4957-62
pubmed: 21890643
Blood. 2011 Nov 3;118(18):4963-6
pubmed: 21835955
Am J Med Genet. 2000 Apr 24;91(5):368-76
pubmed: 10767001
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1568-1577
pubmed: 30716504
N Engl J Med. 2019 Jan 10;380(2):163-170
pubmed: 30625055
Expert Opin Orphan Drugs. 2017;5(10):813-825
pubmed: 29057173
Eur J Hum Genet. 2011 Jan;19(1):18-22
pubmed: 20717171
Blood. 2017 Dec 7;130(23):2491-2498
pubmed: 29066537
Blood. 2000 Jan 1;95(1):320-7
pubmed: 10607719
Blood. 2014 Apr 10;123(15):2308-16
pubmed: 24523241
Orphanet J Rare Dis. 2012 Sep 25;7:71
pubmed: 23009155
Support Cancer Ther. 2006 Jul 1;3(4):220-31
pubmed: 18632498
N Engl J Med. 2009 Jan 1;360(1):32-43
pubmed: 19118303
Br J Haematol. 2014 Jan;164(1):15-23
pubmed: 24111611
J Pediatr Hematol Oncol. 1997 Sep-Oct;19(5):443-8
pubmed: 9329467